Condition

Hodgkin lymphoma

Clinical trials and treatment information for Hodgkin lymphoma

362K

People Affected

Active Trials

65K

New Cases/Year

28K

Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine)

85% Effectiveness• 95% Confidence• 25% Safety• 48 trials• 75K participants

HIGH EvidenceExcellent ValueDose: Standardized regimen (e.g., Doxorubicin 25mg/m2, Bleomycin 10mg/m2, Vinblastine 6mg/m2, Dacarbazine 375mg/m2, on days 1 & 15 of 28-day cycles)

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Weeks to months

Duration

4-6 months

Response Rate

85%

Remission Rate

75%

Common Side Effects:

Nausea/Vomiting: 80%

Hair Loss: 100%

Fatigue: 75%

Neutropenia: 60%

Bleomycin-induced Lung Toxicity: 10%

Cardiotoxicity (Doxorubicin): 5%

Annual Cost of Care

Drug Cost

$12,000

Monitoring

$10,000

Side Effects

$7,500

Total Annual

$29,500

Cost-Effectiveness

EXCELLENT

QALYs Gained

Cost per Remission

$39,333

Cost per Responder

$34,706

Treatment Outcomes

Primary Outcomes

Complete Remission (CR) Rate0% (pre-treatment)

+85% (85% of patients achieve CR)

5-Year Progression-Free Survival (PFS) Rate0% without treatment

+80% (80% of patients progression-free at 5 years)

5-Year Overall Survival (OS) Rate0% without treatment

+92% (92% of patients alive at 5 years)

FDG-PET SUVmaxSUVmax 12 (Deauville 4-5, metabolically active disease)

-85% (-10.2 SUVmax units (e.g., from 12 to 1.8))

Secondary Benefits

FACT-Lym Score (Quality of Life)Score 90/136 (moderate impairment)

+11.1% (+10 points)

ECOG Performance StatusECOG score: 2 (symptomatic but ambulatory)

-50% (-1 point (e.g., from ECOG 2 to 1))

Resolution of B SymptomsPresence of B symptoms (prior to treatment)

+85% (85% of patients with B symptoms achieve resolution)

Common Side Effects

Nausea/Vomiting

+80%

Hair Loss

+100%

Fatigue

+75%

Clinical Trial Phases:

Phase 3Phase 4

BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)

90% Effectiveness• 90% Confidence• 25% Safety• 12 trials• 15K participants

HIGH EvidenceModerate ValueDose: Standardized regimen (e.g., EscBEACOPP: Bleomycin 10mg/m2, Etoposide 200mg/m2, Doxorubicin 35mg/m2, Cyclophosphamide 1250mg/m2, Vincristine 1.4mg/m2, Procarbazine 100mg/m2, Prednisone 40mg/m2)

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Weeks to months

Duration

4-8 months

Response Rate

90%

Remission Rate

85%

Common Side Effects:

Severe Myelosuppression (Neutropenia, Thrombocytopenia): 85%

Hair Loss: 100%

Nausea/Vomiting: 90%

Infertility: 40%

Secondary Malignancies: 5%

Annual Cost of Care

Drug Cost

$25,000

Monitoring

$15,000

Side Effects

$18,000

Total Annual

$58,000

Cost-Effectiveness

MODERATE

QALYs Gained

25.8

Cost per Remission

$68,235

Cost per Responder

$64,444

Treatment Outcomes

Primary Outcomes

Complete Remission RateActive Hodgkin Lymphoma disease (0% complete remission)

+88% (88% of patients)

5-Year Progression-Free Survival Rate0% Progression-Free Survival at 5 years (hypothetical untreated)

+85% (85% of patients)

5-Year Overall Survival Rate0% Overall Survival at 5 years (hypothetical untreated)

+90% (90% of patients)

Early PET Response (Deauville Score 1-3) RateActive disease (Deauville score 4-5)

+80% (80% of patients achieve Deauville 1-3)

Secondary Benefits

Quality of Life (EORTC QLQ-C30 Global Health Status)50/100 (pre-treatment, symptomatic)

+20% (+10 points on scale)

ECOG Performance Status ImprovementECOG Performance Status: 1 (symptomatic)

-100% (-1 point (e.g., from 1 to 0))

Resolution of B Symptoms (Fever, Night Sweats, Weight Loss)Presence of B symptoms in 100% of symptomatic patients

-95% (Resolution in 95% of patients)

Common Side Effects

Severe Myelosuppression (Neutropenia, Thrombocytopenia)

+85%

Hair Loss

+100%

Nausea/Vomiting

+90%

Clinical Trial Phases:

Phase 3Phase 4

Brentuximab vedotin + AVD (Doxorubicin, Vinblastine, Dacarbazine)

88% Effectiveness• 90% Confidence• 30% Safety• 19 trials• 8K participants

HIGH EvidencePoor ValueDose: Brentuximab vedotin 1.2 mg/kg, Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, Dacarbazine 375 mg/m2, on days 1 & 15 of 21-day cycles

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Weeks to months

Duration

6 months

Response Rate

90%

Remission Rate

75%

Number Needed to Treat (NNT)

Number Needed to Harm (NNH)

Common Side Effects:

Peripheral Neuropathy: 55%

Neutropenia: 45%

Fatigue: 35%

Nausea: 35%

Hair Loss: 35%

Annual Cost of Care

Drug Cost

$150,000

Monitoring

$10,000

Side Effects

$7,500

Total Annual

$167,500

Cost-Effectiveness

POOR

QALYs Gained

ICER

$197,295/QALY

Cost per Remission

$223,333

Cost per Responder

$186,111

Treatment Outcomes

Primary Outcomes

3-Year Event-Free Survival (EFS) Rate76.9% (with ABVD regimen)

+8.06% (+6.2 percentage points)

Complete Remission (CR) Rate (End of Treatment)75% (with ABVD regimen)

+9.33% (+7 percentage points)

PET-Negative Status Rate (Deauville 1-3) Post-Treatment78% (with ABVD regimen)

+12.82% (+10 percentage points)

Secondary Benefits

3-Year Overall Survival (OS) Rate90.9% (with ABVD regimen)

+1.43% (+1.3 percentage points)

Rate of Resolution of B Symptoms (by Cycle 2)60% (with ABVD regimen)

+25% (+15 percentage points)

Common Side Effects

Peripheral Neuropathy

+55%

Neutropenia

+45%

Fatigue

+35%

Clinical Trial Phases:

Phase 3Phase 4

External Beam Radiation Therapy (EBRT)

80% Effectiveness• 95% Confidence• 25% Safety• 13 trials• 50K participants

HIGH EvidenceGood ValueDose: 20-36 Gy in 10-20 fractions

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

During/shortly after treatment

Duration

2-4 weeks

Response Rate

90%

Remission Rate

85%

Common Side Effects:

Fatigue: 60%

Skin Irritation: 70%

Dysphagia (neck RT): 40%

Pneumonitis (chest RT): 7%

Hypothyroidism (neck RT, long-term): 25%

Annual Cost of Care

Drug Cost

Monitoring

$5,000

Side Effects

$2,500

Total Annual

$42,500

Cost-Effectiveness

GOOD

QALYs Gained

1.5

Cost per Remission

$50,000

Cost per Responder

$47,222

Treatment Outcomes

Primary Outcomes

SUVmax of Target Lesion (PET-CT)10.0 (typical for active Hodgkin lymphoma)

-85% (-8.5 units)

Sum of Longest Diameters of Target Lymph Nodes (RECIST)10.0 cm (example sum for multiple nodes)

-70% (-7.0 cm)

Pain Intensity (NRS 0-10 scale)7/10 (severe pain for affected patients)

-70% (-4.9 points on 0-10 scale)

Secondary Benefits

Resolution of Systemic Symptoms (B symptoms)100% of affected patients experiencing symptoms

-90% (-90 percentage points of affected patients)

FACT-G Fatigue Subscale Score (higher score indicates less fatigue)15/52 (moderate-severe fatigue)

+30% (+4.5 points on 0-52 scale)

EORTC QLQ-C30 Global Health Status Score (higher score indicates better QoL)50/100 (average for cancer patients)

+20% (+10 points on 0-100 scale)

Common Side Effects

Fatigue

+60%

Skin Irritation

+70%

Dysphagia (neck RT)

+40%

Clinical Trial Phases:

Phase 3Phase 4

Autologous Stem Cell Transplant (ASCT)

75% Effectiveness• 90% Confidence• 20% Safety• 117 trials• 10K participants

HIGH EvidenceModerate ValueDose: High-dose chemotherapy (e.g., BEAM regimen) followed by autologous stem cell infusion

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Engraftment in 2-4 weeks, recovery 3-6 months

Duration

Hospitalization 3-4 weeks, full recovery 6-12 months

Response Rate

60%

Remission Rate

40%

Common Side Effects:

Severe Myelosuppression: 100%

Mucositis: 85%

Infection: 60%

Fatigue: 90%

Infertility: 70%

Secondary Malignancies: 5%

Annual Cost of Care

Drug Cost

$10,000

Monitoring

$15,000

Side Effects

$20,000

Total Annual

$195,000

Cost-Effectiveness

MODERATE

QALYs Gained

Cost per Remission

$487,500

Cost per Responder

$325,000

Treatment Outcomes

Primary Outcomes

5-year Progression-Free Survival Probability20% (estimated without ASCT for relapsed/refractory HL)

+200% (+40 percentage points)

Overall Response Rate (Complete + Partial Remission)30% (ORR after salvage chemotherapy prior to ASCT)

+166.7% (+50 percentage points)

Metabolic Tumor Volume (MTV) Reduction on PET150 cm^3 (example for active disease)

-90% (-135 cm^3)

5-year Overall Survival Probability40% (estimated without ASCT for relapsed/refractory HL)

+75% (+30 percentage points)

Secondary Benefits

EQ-5D Health-related Quality of Life Score0.65 (active disease, scale 0-1)

+20% (+0.13 points)

ECOG Performance Status Score2 (symptomatic, in bed <50% of the day, scale 0-5)

-50% (-1 point)

Lymphoma Symptom Scale Score18/30 (example score for active disease)

-60% (-10.8 points)

Common Side Effects

Severe Myelosuppression

+100%

Mucositis

+85%

Infection

+60%

Clinical Trial Phases:

Phase 3Phase 4

Nivolumab (PD-1 inhibitor)

70% Effectiveness• 85% Confidence• 45% Safety• 14 trials• 3K participants

HIGH EvidencePoor ValueDose: 240 mg IV every 2 weeks or 480 mg IV every 4 weeks

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Weeks to months

Duration

Until progression or unacceptable toxicity (can be years)

Response Rate

65%

Remission Rate

25%

Common Side Effects:

Fatigue: 35%

Rash: 25%

Diarrhea: 20%

Pruritus: 25%

Hypothyroidism (Immune-related): 15%

Pneumonitis (Immune-related): 4%

Annual Cost of Care

Drug Cost

$160,000

Monitoring

$7,500

Side Effects

$5,000

Total Annual

$172,500

Cost-Effectiveness

POOR

QALYs Gained

ICER

$500,000/QALY

Cost per Remission

$690,000

Cost per Responder

$265,385

Treatment Outcomes

Primary Outcomes

Sum of Longest Diameters (SLD) of Target Lesions150 mm

-60% (-90 mm)

SUVmax of Most Avid Lesion on PET18

-80% (-14.4)

B-symptom Severity Score6 (on a 0-9 scale, higher is worse)

-66.7% (-4 points)

Secondary Benefits

EORTC QLQ-C30 Global Health Status Score40 (on a 0-100 scale, higher is better)

+37.5% (+15 points)

EORTC QLQ-C30 Fatigue Scale Score70 (on a 0-100 scale, higher is worse)

-42.8% (-30 points)

ECOG Performance Status2 (on a 0-5 scale, lower is better)

-50% (-1 point)

Common Side Effects

Fatigue

+35%

Rash

+25%

Diarrhea

+20%

Clinical Trial Phases:

Phase 2Phase 3